Cutaneous Lupus Erythematosus (CLE) Market Insights, Epidemiology and Market Forecast
This report can be delivered to the clients within 24 hours
DelveInsight’s ‘Cutaneous Lupus Erythematosus (CLE) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cutaneous Lupus Erythematosus in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cutaneous Lupus Erythematosus from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Cutaneous Lupus Erythematosus - Disease Understanding and Treatment Algorithm
The DelveInsight Cutaneous Lupus Erythematosus market report gives the thorough understanding of CLE by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cutaneous Lupus Erythematosus in the US, Europe, and Japan.
Cutaneous Lupus Erythematosus Epidemiology
The Cutaneous Lupus Erythematosus epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by Total Prevalent cases, Gender specific cases, Diagnosed cases, Type-specific cases [Acute Cutaneous Lupus Erythematosus (ACLE), Subacute Cutaneous Lupus Erythematosus (SCLE), Chronic Cutaneous Lupus Erythematosus (CCLE) {CCLE including Discoid lupus erythematosus (DLE) and other subtypes including lupus erythematosus tumidus, Chilblain’s lupus, bullous SLE, lupus panniculitis etc.}] and Severity-specific cases [Mild, Moderate and Severe] in the 7MM.
According to DelveInsight, the total prevalent cases of Cutaneous Lupus Erythematosus were 327,569 in 2017 in 7MM.
Cutaneous Lupus Erythematosus Drug Chapters
This segment of the Cutaneous Lupus Erythematosus report encloses the detailed analysis of marketed drugs and late stage (Phase-II & III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Cutaneous Lupus Erythematosus Market Outlook
The Cutaneous Lupus Erythematosus market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The current market of CLE is majorly driven by the evidence-based approach with the use of Topical therapies (such as steroids, calcineurin Inhibitor, topical retinoid and other) and Systemic Therapies (such as antimalarial, immunosupressants, immunomodulators and others). The market is filled with antimalarial as first line and long-term agents with use of Hydroxychloroquine, Quinacrine, and Chloroquine. Immunosuppressive agents such as methotrexate (MTX), mycophenolate mofetil (MMF), Azathioprine and Immunomodulators such as Dapsone and others are second- and third-line treatment options. However, all these available therapies have many limitations and most of the therapies have some adverse effects. Additionally, there is a lack of robust clinical trial data to support their use. So, there is a high urgent demand for novel therapies that can overcome the limitations of existing therapies. Although the recent decades are the renaissance for CLE as the research in lupus is being refined to facilitate diagnostic and research protocols. As per DelveInsight estimates, the market size of CLE was found to be USD 485.27 million in 2017. This market is further expected to grow during the forecasted period of 2019-2028 owing to the launch of upcoming therapies. Detailed chapters of the promising upcoming therapies including BIIB059 (Biogen), Etanercept (Pifzer), Filgotinib (Galapagos NV /Gilead Sciences), VIB7734 (Viela Bio), Delgocitinib (LEO Pharma), GS-9876 (Gilead Sciences), Secukinumab (Novartis), and Tofacitinib (Pfizer)are also provided in the report.
Cutaneous Lupus Erythematosus Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Cutaneous Lupus Erythematosus Report Insights
DelveInsight’s ‘Cutaneous Lupus Erythematosus (CLE) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cutaneous Lupus Erythematosus in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cutaneous Lupus Erythematosus from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Cutaneous Lupus Erythematosus - Disease Understanding and Treatment Algorithm
The DelveInsight Cutaneous Lupus Erythematosus market report gives the thorough understanding of CLE by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cutaneous Lupus Erythematosus in the US, Europe, and Japan.
Cutaneous Lupus Erythematosus Epidemiology
The Cutaneous Lupus Erythematosus epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by Total Prevalent cases, Gender specific cases, Diagnosed cases, Type-specific cases [Acute Cutaneous Lupus Erythematosus (ACLE), Subacute Cutaneous Lupus Erythematosus (SCLE), Chronic Cutaneous Lupus Erythematosus (CCLE) {CCLE including Discoid lupus erythematosus (DLE) and other subtypes including lupus erythematosus tumidus, Chilblain’s lupus, bullous SLE, lupus panniculitis etc.}] and Severity-specific cases [Mild, Moderate and Severe] in the 7MM.
According to DelveInsight, the total prevalent cases of Cutaneous Lupus Erythematosus were 327,569 in 2017 in 7MM.
Cutaneous Lupus Erythematosus Drug Chapters
This segment of the Cutaneous Lupus Erythematosus report encloses the detailed analysis of marketed drugs and late stage (Phase-II & III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Cutaneous Lupus Erythematosus Market Outlook
The Cutaneous Lupus Erythematosus market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The current market of CLE is majorly driven by the evidence-based approach with the use of Topical therapies (such as steroids, calcineurin Inhibitor, topical retinoid and other) and Systemic Therapies (such as antimalarial, immunosupressants, immunomodulators and others). The market is filled with antimalarial as first line and long-term agents with use of Hydroxychloroquine, Quinacrine, and Chloroquine. Immunosuppressive agents such as methotrexate (MTX), mycophenolate mofetil (MMF), Azathioprine and Immunomodulators such as Dapsone and others are second- and third-line treatment options. However, all these available therapies have many limitations and most of the therapies have some adverse effects. Additionally, there is a lack of robust clinical trial data to support their use. So, there is a high urgent demand for novel therapies that can overcome the limitations of existing therapies. Although the recent decades are the renaissance for CLE as the research in lupus is being refined to facilitate diagnostic and research protocols. As per DelveInsight estimates, the market size of CLE was found to be USD 485.27 million in 2017. This market is further expected to grow during the forecasted period of 2019-2028 owing to the launch of upcoming therapies. Detailed chapters of the promising upcoming therapies including BIIB059 (Biogen), Etanercept (Pifzer), Filgotinib (Galapagos NV /Gilead Sciences), VIB7734 (Viela Bio), Delgocitinib (LEO Pharma), GS-9876 (Gilead Sciences), Secukinumab (Novartis), and Tofacitinib (Pfizer)are also provided in the report.
Cutaneous Lupus Erythematosus Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Cutaneous Lupus Erythematosus Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Cutaneous Lupus Erythematosus market
- Organize sales and marketing efforts by identifying the best opportunities for Cutaneous Lupus Erythematosus market
- To understand the future market competition in the Cutaneous Lupus Erythematosus market.
1. KEY INSIGHTS
2. CUTANEOUS LUPUS ERYTHEMATOSUS (CLE): MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share (%) Distribution of Cutaneous Lupus Erythematosus (CLE) in 2017
2.2. Total Market Share (%) Distribution of Cutaneous Lupus Erythematosus (CLE) in 2028
3. DISEASE BACKGROUND AND OVERVIEW: CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
3.1. Introduction
3.2. Signs and Symptoms
3.3. Classification of Cutaneous Lupus Erythematosus
3.4. Etiology
3.5. Genetic Bases of Cutaneous Lupus Erythematosus
3.6. Pathogenesis
3.7. Diagnosis
3.7.1. Diagnosis criteria for the sub-types of CLE
3.7.2. Diagnosis Guidelines
3.7.3. S2k - European Dermatology Forum (EDF) Guideline on Diagnosis and Monitoring in Cutaneous Lupus Erythematosus
3.7.4. Differential Diagnosis
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Prevalent cases of Cutaneous Lupus Erythematosus in 7MM
4.3. United States
4.3.1. Assumptions and Rationale
4.3.2. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.3. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.4. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.5. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.6. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.4. EU-5
4.4.1. Assumptions and Rationale
4.5. Germany
4.5.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.6. France
4.6.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in France
4.7. Italy
4.7.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.8. Spain
4.8.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.9. United Kingdom
4.9.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.10. Japan
4.10.1. Assumptions and Rationale
4.10.2. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.3. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.4. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.5. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.6. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Japan
5. TREATMENT AND MANAGEMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS
5.1. S2k Guideline for Treatment of Cutaneous Lupus Erythematosus
5.2. Treatment Benefits Based on the Oxford Centre for Evidence-based Medicine Criteria
6. UNMET NEEDS
7. EMERGING DRUGS
7.1. Key Cross Competition
7.2. BIIB059: Biogen
7.2.1. Drug Description
7.2.2. Other Developmental Activities
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. Etanercept: Pfizer
7.3.1. Drug Description
7.3.2. Other Developmental Activities
7.3.3. Clinical Development
7.3.4. Safety and Efficacy
7.3.5. Product Profile
7.4. Filgotinib: Galapagos NV /Gilead Sciences
7.4.1. Drug Description
7.4.2. Other Developmental Activities
7.4.3. Clinical Development
7.4.4. Product Profile
7.5. GS-9876: Gilead Sciences
7.6. Drug Description
7.7. Other Developmental Activities
7.8. Clinical Development
7.9. Product Profile
7.10. Delgocitinib: LEO Pharma/ Japan Tobacco
7.10.1. Product Description
7.10.2. Other Developmental Activities
7.10.3. Clinical Development
7.10.4. Product Profile
7.11. VIB7734: VIELABIO
7.11.1. Drug Description
7.11.2. Other Developmental Activities
7.11.3. Clinical Development
7.11.4. Product Profile
8. CUTANEOUS LUPUS ERYTHEMATOSUS (CLE): MARKET ANALYSIS
8.1. Key Findings
8.2. Market Size of Cutaneous Lupus Erythematosus (CLE) in 7MM
8.3. US: Market Outlook
8.3.1. US Market Size
8.3.2. Market size of Cutaneous Lupus Erythematosus (CLE) in the US
8.3.3. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.4. EU-5: Market outlook
8.5. Germany
8.5.1. Market size of Cutaneous Lupus Erythematosus (CLE) in Germany
8.5.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.6. France
8.6.1. Market size of Cutaneous Lupus Erythematosus (CLE) in France
8.6.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.7. Italy
8.7.1. Market size of Cutaneous Lupus Erythematosus (CLE) in Italy
8.7.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.8. Spain
8.8.1. Market size of Cutaneous Lupus Erythematosus (CLE) in Spain
8.8.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.9. United Kingdom
8.9.1. Market size Cutaneous Lupus Erythematosus (CLE) in the UK
8.9.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.10. Japan: Market Outlook
8.10.1. Japan Market Size
8.10.2. Market size of Cutaneous Lupus Erythematosus (CLE) in Japan
8.10.3. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
9. MARKET DRIVERS
10. MARKET BARRIERS
11. APPENDIX
12. REPORT METHODOLOGY
13. DELVEINSIGHT CAPABILITIES
14. DISCLAIMER
15. ABOUT DELVEINSIGHT
2. CUTANEOUS LUPUS ERYTHEMATOSUS (CLE): MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share (%) Distribution of Cutaneous Lupus Erythematosus (CLE) in 2017
2.2. Total Market Share (%) Distribution of Cutaneous Lupus Erythematosus (CLE) in 2028
3. DISEASE BACKGROUND AND OVERVIEW: CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
3.1. Introduction
3.2. Signs and Symptoms
3.3. Classification of Cutaneous Lupus Erythematosus
3.4. Etiology
3.5. Genetic Bases of Cutaneous Lupus Erythematosus
3.6. Pathogenesis
3.7. Diagnosis
3.7.1. Diagnosis criteria for the sub-types of CLE
3.7.2. Diagnosis Guidelines
3.7.3. S2k - European Dermatology Forum (EDF) Guideline on Diagnosis and Monitoring in Cutaneous Lupus Erythematosus
3.7.4. Differential Diagnosis
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Prevalent cases of Cutaneous Lupus Erythematosus in 7MM
4.3. United States
4.3.1. Assumptions and Rationale
4.3.2. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.3. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.4. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.5. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.6. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.4. EU-5
4.4.1. Assumptions and Rationale
4.5. Germany
4.5.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.6. France
4.6.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in France
4.7. Italy
4.7.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.8. Spain
4.8.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.9. United Kingdom
4.9.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.10. Japan
4.10.1. Assumptions and Rationale
4.10.2. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.3. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.4. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.5. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.6. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Japan
5. TREATMENT AND MANAGEMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS
5.1. S2k Guideline for Treatment of Cutaneous Lupus Erythematosus
5.2. Treatment Benefits Based on the Oxford Centre for Evidence-based Medicine Criteria
6. UNMET NEEDS
7. EMERGING DRUGS
7.1. Key Cross Competition
7.2. BIIB059: Biogen
7.2.1. Drug Description
7.2.2. Other Developmental Activities
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. Etanercept: Pfizer
7.3.1. Drug Description
7.3.2. Other Developmental Activities
7.3.3. Clinical Development
7.3.4. Safety and Efficacy
7.3.5. Product Profile
7.4. Filgotinib: Galapagos NV /Gilead Sciences
7.4.1. Drug Description
7.4.2. Other Developmental Activities
7.4.3. Clinical Development
7.4.4. Product Profile
7.5. GS-9876: Gilead Sciences
7.6. Drug Description
7.7. Other Developmental Activities
7.8. Clinical Development
7.9. Product Profile
7.10. Delgocitinib: LEO Pharma/ Japan Tobacco
7.10.1. Product Description
7.10.2. Other Developmental Activities
7.10.3. Clinical Development
7.10.4. Product Profile
7.11. VIB7734: VIELABIO
7.11.1. Drug Description
7.11.2. Other Developmental Activities
7.11.3. Clinical Development
7.11.4. Product Profile
8. CUTANEOUS LUPUS ERYTHEMATOSUS (CLE): MARKET ANALYSIS
8.1. Key Findings
8.2. Market Size of Cutaneous Lupus Erythematosus (CLE) in 7MM
8.3. US: Market Outlook
8.3.1. US Market Size
8.3.2. Market size of Cutaneous Lupus Erythematosus (CLE) in the US
8.3.3. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.4. EU-5: Market outlook
8.5. Germany
8.5.1. Market size of Cutaneous Lupus Erythematosus (CLE) in Germany
8.5.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.6. France
8.6.1. Market size of Cutaneous Lupus Erythematosus (CLE) in France
8.6.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.7. Italy
8.7.1. Market size of Cutaneous Lupus Erythematosus (CLE) in Italy
8.7.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.8. Spain
8.8.1. Market size of Cutaneous Lupus Erythematosus (CLE) in Spain
8.8.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.9. United Kingdom
8.9.1. Market size Cutaneous Lupus Erythematosus (CLE) in the UK
8.9.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.10. Japan: Market Outlook
8.10.1. Japan Market Size
8.10.2. Market size of Cutaneous Lupus Erythematosus (CLE) in Japan
8.10.3. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
9. MARKET DRIVERS
10. MARKET BARRIERS
11. APPENDIX
12. REPORT METHODOLOGY
13. DELVEINSIGHT CAPABILITIES
14. DISCLAIMER
15. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Types of cutaneous lupus erythematosus (CLE)
Table 2: Histopathology of cutaneous LE lesions
Table 3: Laboratory tests in cutaneous lupus erythematosus
Table 4: Technical investigation
Table 5: Diagnostic criteria for discoid lupus erythematosus
Table 6: Diagnostic criteria for Chilblain Lupus
Table 7: Diagnostic criteria for Lupus Erythematosus Tumidus
Table 8: Diagnostic criteria for lupus panniculitis
Table 9: Diagnostic criteria for subacute cutaneous lupus erythematosus
Table 10: Diagnostic criteria for acute cutaneous lupus erythematosus
Table 11: Recommendations
Table 12: ACR Criteria/SLICC Criteria Recommendations
Table 13: Histology and Direct immunofluorescence Recommendations
Table 14: Photoprovocation Recommendations
Table 15: Laboratory Diagnostics Recommendations
Table 16: Differential diagnoses of cutaneous lupus erythematosus
Table 17: Total Prevalent cases of CLE in 7MM (2017-2028)
Table 18: Total Prevalent Cases of CLE in the US (2017-2028)
Table 19: Gender Specific Prevalent Cases of CLE in the US (2017-2028)
Table 20: Diagnosed Cases of CLE in the US (2017-2028)
Table 21: Type Specific Prevalent Cases of CLE in the US (2017-2028)
Table 22: Severity Specific Prevalent Cases of CLE in the US (2017-2028)
Table 23: Total Prevalent Cases of CLE in Germany (2017-2028)
Table 24: Gender Specific Prevalent Cases of CLE in Germany (2017-2028)
Table 25: Diagnosed Cases of CLE in Germany (2017-2028)
Table 26: Type Specific Prevalent Cases of CLE in Germany (2017-2028)
Table 27: Severity Specific Prevalent Cases of CLE in Germany (2017-2028)
Table 28: Total Prevalent Cases of CLE in France (2017-2028)
Table 29: Gender Specific Prevalent Cases of CLE in France (2017-2028)
Table 30: Diagnosed Cases of CLE in France (2017-2028)
Table 31: Type Specific Prevalent Cases of CLE in France (2017-2028)
Table 32: Severity Specific Prevalent Cases of CLE in France (2017-2028)
Table 33: Total Prevalent Cases of CLE in Italy (2017-2028)
Table 34: Gender Specific Prevalent Cases of CLE in Italy (2017-2028)
Table 35: Diagnosed Cases of CLE in Italy (2017-2028)
Table 36: Type Specific Prevalent Cases of CLE in Italy (2017-2028)
Table 37: Severity Specific Prevalent Cases of CLE in Italy (2017-2028)
Table 38: Total Prevalent Cases of CLE in Spain (2017-2028)
Table 39: Gender Specific Prevalent Cases of CLE in Spain (2017-2028)
Table 40: Diagnosed Cases of CLE in Spain (2017-2028)
Table 41: Type Specific Prevalent Cases of CLE in Spain (2017-2028)
Table 42: Severity Specific Prevalent Cases of CLE in Spain (2017-2028)
Table 43: Total Prevalent Cases of CLE in the UK (2017-2028)
Table 44: Gender Specific Prevalent Cases of CLE in the UK (2017-2028)
Table 45: Diagnosed Cases of CLE in the UK (2017-2028)
Table 46: Type Specific Prevalent Cases of CLE in the UK (2017-2028)
Table 47: Severity Specific Prevalent Cases of CLE in the UK (2017-2028)
Table 48: Total Prevalent Cases of CLE in Japan (2017-2028)
Table 49: Gender Specific Prevalent Cases of CLE in Japan (2017-2028)
Table 50: Diagnosed Cases of CLE in Japan (2017-2028)
Table 51: Type Specific Prevalent Cases of CLE in Japan (2017-2028)
Table 52: Severity Specific Prevalent Cases of CLE in Japan (2017-2028)
Table 53: Preventive Measures and Risk Factors Recommendations
Table 54: Pregnancy or Hormonal Therapy Recommendations
Table 55: Topical Treatment Recommendations
Table 56: UV Treatment, Cryotherapy, and Lasers Recommendations
Table 57: Oxford Centre for Evidence-Based Medicine 2011 Treatment Benefit Levels of Evidence
Table 58: Combination therapy in cutaneous lupus erythematous
Table 59: Therapies for cutaneous lupus erythematosus and the levels of evidence supporting therapeutic benefit according to the Oxford Centre for Evidence-Based Medicine Criteria
Table 60: Summary of cutaneous lupus erythematosus therapeutic interventions
Table 61: Emerging Drugs Analysis
Table 62: BIIB059, Clinical Trial Description, 2019
Table 63: Etanercept, Clinical Trial Description, 2019
Table 64: Filgotinib, Clinical Trial Description, 2019
Table 65: GS-9876, Clinical Trial Description, 2019
Table 66: Delgocitinib, Clinical Trial Description, 2019
Table 67: VIB7734, Clinical Trial Description, 2019
Table 68: Market Size of CLE in 7MM in USD Million (2017-2028)
Table 69: Market size of CLE in the US (2017-2028)
Table 70: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 71: Market size of CLE in Germany (2017-2028)
Table 72: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 73: Market size of CLE in France (2017-2028)
Table 74: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 75: Market size of CLE in Italy (2017-2028)
Table 76: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 77: Market size of cutaneous lupus erythematosus (CLE) in Spain (2017-2028)
Table 78: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 79: Market size of CLE in the UK (2017-2028)
Table 80: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 81: Market size of CLE in Japan (2017-2028)
Table 82: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 1: Types of cutaneous lupus erythematosus (CLE)
Table 2: Histopathology of cutaneous LE lesions
Table 3: Laboratory tests in cutaneous lupus erythematosus
Table 4: Technical investigation
Table 5: Diagnostic criteria for discoid lupus erythematosus
Table 6: Diagnostic criteria for Chilblain Lupus
Table 7: Diagnostic criteria for Lupus Erythematosus Tumidus
Table 8: Diagnostic criteria for lupus panniculitis
Table 9: Diagnostic criteria for subacute cutaneous lupus erythematosus
Table 10: Diagnostic criteria for acute cutaneous lupus erythematosus
Table 11: Recommendations
Table 12: ACR Criteria/SLICC Criteria Recommendations
Table 13: Histology and Direct immunofluorescence Recommendations
Table 14: Photoprovocation Recommendations
Table 15: Laboratory Diagnostics Recommendations
Table 16: Differential diagnoses of cutaneous lupus erythematosus
Table 17: Total Prevalent cases of CLE in 7MM (2017-2028)
Table 18: Total Prevalent Cases of CLE in the US (2017-2028)
Table 19: Gender Specific Prevalent Cases of CLE in the US (2017-2028)
Table 20: Diagnosed Cases of CLE in the US (2017-2028)
Table 21: Type Specific Prevalent Cases of CLE in the US (2017-2028)
Table 22: Severity Specific Prevalent Cases of CLE in the US (2017-2028)
Table 23: Total Prevalent Cases of CLE in Germany (2017-2028)
Table 24: Gender Specific Prevalent Cases of CLE in Germany (2017-2028)
Table 25: Diagnosed Cases of CLE in Germany (2017-2028)
Table 26: Type Specific Prevalent Cases of CLE in Germany (2017-2028)
Table 27: Severity Specific Prevalent Cases of CLE in Germany (2017-2028)
Table 28: Total Prevalent Cases of CLE in France (2017-2028)
Table 29: Gender Specific Prevalent Cases of CLE in France (2017-2028)
Table 30: Diagnosed Cases of CLE in France (2017-2028)
Table 31: Type Specific Prevalent Cases of CLE in France (2017-2028)
Table 32: Severity Specific Prevalent Cases of CLE in France (2017-2028)
Table 33: Total Prevalent Cases of CLE in Italy (2017-2028)
Table 34: Gender Specific Prevalent Cases of CLE in Italy (2017-2028)
Table 35: Diagnosed Cases of CLE in Italy (2017-2028)
Table 36: Type Specific Prevalent Cases of CLE in Italy (2017-2028)
Table 37: Severity Specific Prevalent Cases of CLE in Italy (2017-2028)
Table 38: Total Prevalent Cases of CLE in Spain (2017-2028)
Table 39: Gender Specific Prevalent Cases of CLE in Spain (2017-2028)
Table 40: Diagnosed Cases of CLE in Spain (2017-2028)
Table 41: Type Specific Prevalent Cases of CLE in Spain (2017-2028)
Table 42: Severity Specific Prevalent Cases of CLE in Spain (2017-2028)
Table 43: Total Prevalent Cases of CLE in the UK (2017-2028)
Table 44: Gender Specific Prevalent Cases of CLE in the UK (2017-2028)
Table 45: Diagnosed Cases of CLE in the UK (2017-2028)
Table 46: Type Specific Prevalent Cases of CLE in the UK (2017-2028)
Table 47: Severity Specific Prevalent Cases of CLE in the UK (2017-2028)
Table 48: Total Prevalent Cases of CLE in Japan (2017-2028)
Table 49: Gender Specific Prevalent Cases of CLE in Japan (2017-2028)
Table 50: Diagnosed Cases of CLE in Japan (2017-2028)
Table 51: Type Specific Prevalent Cases of CLE in Japan (2017-2028)
Table 52: Severity Specific Prevalent Cases of CLE in Japan (2017-2028)
Table 53: Preventive Measures and Risk Factors Recommendations
Table 54: Pregnancy or Hormonal Therapy Recommendations
Table 55: Topical Treatment Recommendations
Table 56: UV Treatment, Cryotherapy, and Lasers Recommendations
Table 57: Oxford Centre for Evidence-Based Medicine 2011 Treatment Benefit Levels of Evidence
Table 58: Combination therapy in cutaneous lupus erythematous
Table 59: Therapies for cutaneous lupus erythematosus and the levels of evidence supporting therapeutic benefit according to the Oxford Centre for Evidence-Based Medicine Criteria
Table 60: Summary of cutaneous lupus erythematosus therapeutic interventions
Table 61: Emerging Drugs Analysis
Table 62: BIIB059, Clinical Trial Description, 2019
Table 63: Etanercept, Clinical Trial Description, 2019
Table 64: Filgotinib, Clinical Trial Description, 2019
Table 65: GS-9876, Clinical Trial Description, 2019
Table 66: Delgocitinib, Clinical Trial Description, 2019
Table 67: VIB7734, Clinical Trial Description, 2019
Table 68: Market Size of CLE in 7MM in USD Million (2017-2028)
Table 69: Market size of CLE in the US (2017-2028)
Table 70: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 71: Market size of CLE in Germany (2017-2028)
Table 72: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 73: Market size of CLE in France (2017-2028)
Table 74: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 75: Market size of CLE in Italy (2017-2028)
Table 76: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 77: Market size of cutaneous lupus erythematosus (CLE) in Spain (2017-2028)
Table 78: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 79: Market size of CLE in the UK (2017-2028)
Table 80: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 81: Market size of CLE in Japan (2017-2028)
Table 82: Market Size of CLE by Therapies in USD Million (2017-2028)
LIST OF FIGURES
Figure 1: Common symptoms of Lupus
Figure 2: The inflammatory cascades of cutaneous lupus
Figure 3: Summary of CLE pathogenesis
Figure 4: The autoimmune response of cutaneous lupus
Figure 5: Total Prevalent cases of CLE in 7MM (2017-2028)
Figure 6: Total Prevalent Cases of CLE in the US (2017-2028)
Figure 7: Gender Specific Cases of CLE in the US (2017-2028)
Figure 8: Diagnosed Cases of CLE in the US (2017-2028)
Figure 9: Type Specific Cases of CLE in the US (2017-2028)
Figure 10: Severity Specific Cases of CLE in the US (2017-2028)
Figure 11: Total Prevalent Cases of CLE in Germany (2017-2028)
Figure 12: Gender Specific Cases of CLE in Germany (2017-2028)
Figure 13: Diagnosed Cases of CLE in Germany (2017-2028)
Figure 14: Type Specific Cases of CLE in Germany (2017-2028)
Figure 15: Severity Specific Cases of CLE in Germany (2017-2028)
Figure 16: Total Prevalent Cases of CLE in France (2017-2028)
Figure 17: Gender Specific Cases of CLE in France (2017-2028)
Figure 18: Diagnosed Cases of CLE in France (2017-2028)
Figure 19: Type Specific Cases of CLE in France (2017-2028)
Figure 20: Severity Specific Cases of CLE in France (2017-2028)
Figure 21: Total Prevalent Cases of CLE in Italy (2017-2028)
Figure 22: Gender Specific Cases of CLE in Italy (2017-2028)
Figure 23: Diagnosed Cases of CLE in Italy (2017-2028)
Figure 24: Type Specific Cases of CLE in Italy (2017-2028)
Figure 25: Severity Specific Cases of CLE in Italy (2017-2028)
Figure 26: Total Prevalent Cases of CLE in Spain (2017-2028)
Figure 27: Gender Specific Cases of CLE in Spain (2017-2028)
Figure 28: Diagnosed Cases of CLE in Spain (2017-2028)
Figure 29: Type Specific Cases of CLE in Spain (2017-2028)
Figure 30: Severity Specific Cases of CLE in Spain (2017-2028)
Figure 31: Total Prevalent Cases of CLE in the UK (2017-2028)
Figure 32: Gender Specific Cases of CLE in the UK (2017-2028)
Figure 33: Diagnosed Cases of CLE in the UK (2017-2028)
Figure 34: Type Specific Cases of CLE in the UK (2017-2028)
Figure 35: Severity Specific Cases of CLE in the UK (2017-2028)
Figure 36: Total Prevalent Cases of CLE in Japan (2017-2028)
Figure 37: Gender Specific Cases of CLE in Japan (2017-2028)
Figure 38: Diagnosed Cases of CLE in Japan (2017-2028)
Figure 39: Type Specific Cases of CLE in Japan (2017-2028)
Figure 40: Severity Specific Cases of CLE in Japan (2017-2028)
Figure 41: Subtypes of cutaneous lupus erythematosus (CLE)
Figure 42: Recommended treatments for the CLE
Figure 43: Topical Therapies for the treatment of CLE
Figure 44: Algorithm for cutaneous lupus erythematosus treatment
Figure 45: Unmet Needs
Figure 46: Market Size of CLE in 7MM in USD Million (2017-2028)
Figure 47: Market size of CLE in the US (2017-2028)
Figure 48: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 49: Market size of CLE in Germany (2017-2028)
Figure 50: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 51: Market size of CLE in France (2017-2028)
Figure 52: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 53: Market size of CLE in Italy (2017-2028)
Figure 54: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 55: Market size of CLE in Spain (2017-2028)
Figure 56: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 57: Market size of CLE in the UK (2017-2028)
Figure 58: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 59: Market size of CLE in Japan (2017-2028)
Figure 60: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 61: Market Drivers
Figure 62: Market Barriers
KEY COMPANIES
Biogen
Pfizer
Galapagos NV /Gilead Sciences
Gilead Sciences
LEO Pharma/ Japan Tobacco
VIELABIO
Figure 1: Common symptoms of Lupus
Figure 2: The inflammatory cascades of cutaneous lupus
Figure 3: Summary of CLE pathogenesis
Figure 4: The autoimmune response of cutaneous lupus
Figure 5: Total Prevalent cases of CLE in 7MM (2017-2028)
Figure 6: Total Prevalent Cases of CLE in the US (2017-2028)
Figure 7: Gender Specific Cases of CLE in the US (2017-2028)
Figure 8: Diagnosed Cases of CLE in the US (2017-2028)
Figure 9: Type Specific Cases of CLE in the US (2017-2028)
Figure 10: Severity Specific Cases of CLE in the US (2017-2028)
Figure 11: Total Prevalent Cases of CLE in Germany (2017-2028)
Figure 12: Gender Specific Cases of CLE in Germany (2017-2028)
Figure 13: Diagnosed Cases of CLE in Germany (2017-2028)
Figure 14: Type Specific Cases of CLE in Germany (2017-2028)
Figure 15: Severity Specific Cases of CLE in Germany (2017-2028)
Figure 16: Total Prevalent Cases of CLE in France (2017-2028)
Figure 17: Gender Specific Cases of CLE in France (2017-2028)
Figure 18: Diagnosed Cases of CLE in France (2017-2028)
Figure 19: Type Specific Cases of CLE in France (2017-2028)
Figure 20: Severity Specific Cases of CLE in France (2017-2028)
Figure 21: Total Prevalent Cases of CLE in Italy (2017-2028)
Figure 22: Gender Specific Cases of CLE in Italy (2017-2028)
Figure 23: Diagnosed Cases of CLE in Italy (2017-2028)
Figure 24: Type Specific Cases of CLE in Italy (2017-2028)
Figure 25: Severity Specific Cases of CLE in Italy (2017-2028)
Figure 26: Total Prevalent Cases of CLE in Spain (2017-2028)
Figure 27: Gender Specific Cases of CLE in Spain (2017-2028)
Figure 28: Diagnosed Cases of CLE in Spain (2017-2028)
Figure 29: Type Specific Cases of CLE in Spain (2017-2028)
Figure 30: Severity Specific Cases of CLE in Spain (2017-2028)
Figure 31: Total Prevalent Cases of CLE in the UK (2017-2028)
Figure 32: Gender Specific Cases of CLE in the UK (2017-2028)
Figure 33: Diagnosed Cases of CLE in the UK (2017-2028)
Figure 34: Type Specific Cases of CLE in the UK (2017-2028)
Figure 35: Severity Specific Cases of CLE in the UK (2017-2028)
Figure 36: Total Prevalent Cases of CLE in Japan (2017-2028)
Figure 37: Gender Specific Cases of CLE in Japan (2017-2028)
Figure 38: Diagnosed Cases of CLE in Japan (2017-2028)
Figure 39: Type Specific Cases of CLE in Japan (2017-2028)
Figure 40: Severity Specific Cases of CLE in Japan (2017-2028)
Figure 41: Subtypes of cutaneous lupus erythematosus (CLE)
Figure 42: Recommended treatments for the CLE
Figure 43: Topical Therapies for the treatment of CLE
Figure 44: Algorithm for cutaneous lupus erythematosus treatment
Figure 45: Unmet Needs
Figure 46: Market Size of CLE in 7MM in USD Million (2017-2028)
Figure 47: Market size of CLE in the US (2017-2028)
Figure 48: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 49: Market size of CLE in Germany (2017-2028)
Figure 50: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 51: Market size of CLE in France (2017-2028)
Figure 52: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 53: Market size of CLE in Italy (2017-2028)
Figure 54: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 55: Market size of CLE in Spain (2017-2028)
Figure 56: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 57: Market size of CLE in the UK (2017-2028)
Figure 58: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 59: Market size of CLE in Japan (2017-2028)
Figure 60: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 61: Market Drivers
Figure 62: Market Barriers
KEY COMPANIES
Biogen
Pfizer
Galapagos NV /Gilead Sciences
Gilead Sciences
LEO Pharma/ Japan Tobacco
VIELABIO
